Mind Medicine (MindMed) (NASDAQ:MNMD – Get Free Report) will post its quarterly earnings results after the market closes on Thursday, November 7th. Analysts expect Mind Medicine (MindMed) to post earnings of ($0.29) per share for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.
Mind Medicine (MindMed) (NASDAQ:MNMD – Get Free Report) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.18). On average, analysts expect Mind Medicine (MindMed) to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Mind Medicine (MindMed) Stock Down 1.7 %
Shares of MNMD opened at $6.34 on Thursday. The company has a 50-day simple moving average of $5.99 and a 200-day simple moving average of $7.35. The firm has a market capitalization of $457.40 million, a P/E ratio of -2.60 and a beta of 2.52. The company has a debt-to-equity ratio of 0.12, a quick ratio of 5.92 and a current ratio of 5.92. Mind Medicine has a 52 week low of $2.41 and a 52 week high of $12.22.
Insider Transactions at Mind Medicine (MindMed)
Wall Street Analyst Weigh In
Several research firms recently issued reports on MNMD. Canaccord Genuity Group dropped their price target on shares of Mind Medicine (MindMed) from $16.00 to $14.00 and set a “buy” rating for the company in a research report on Monday, September 16th. Leerink Partners began coverage on shares of Mind Medicine (MindMed) in a research report on Monday, October 14th. They issued an “outperform” rating and a $20.00 price target for the company. HC Wainwright increased their price target on shares of Mind Medicine (MindMed) from $35.00 to $55.00 and gave the stock a “buy” rating in a research report on Thursday, August 29th. Leerink Partnrs raised shares of Mind Medicine (MindMed) to a “strong-buy” rating in a research report on Friday, October 11th. Finally, Roth Mkm began coverage on shares of Mind Medicine (MindMed) in a research report on Wednesday, July 24th. They issued a “buy” rating and a $36.00 price target for the company. Nine analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $25.38.
Read Our Latest Stock Analysis on MNMD
Mind Medicine (MindMed) Company Profile
Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.
Featured Stories
- Five stocks we like better than Mind Medicine (MindMed)
- 3 Best Fintech Stocks for a Portfolio Boost
- Boeing: Why Analysts Think Now’s The Time To Be Brave
- Stock Analyst Ratings and Canadian Analyst Ratings
- Advanced Micro Devices is Building Momentum with AI: Buy the Dip
- What is Forex and How Does it Work?
- Can Evolv Stock Recover From Its Massive Self-Inflicted Drop?
Receive News & Ratings for Mind Medicine (MindMed) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mind Medicine (MindMed) and related companies with MarketBeat.com's FREE daily email newsletter.